%D8%A3%D8%AF%D8%A7%D9%84%D9%8A%D9%85%D9%88%D9%85%D8%A7%D8%A8%D8%A2%D8%AF%D8%A7%D9%84%DB%8C%D9%85%D9%88%D9%85%D8%A8AdalimumabAdalimumabAdalimumabAdalimumab%D8%A2%D8%AF%D8%A7%D9%84%DB%8C%D9%85%D9%88%D9%85%D8%A8AdalimumabiAdalimumab%D7%90%D7%93%D7%9C%D7%99%D7%9E%D7%95%D7%9E%D7%90%D7%91Adalimumab%E3%82%A2%E3%83%80%E3%83%AA%E3%83%A0%E3%83%9E%E3%83%96Adalimumab%E0%AC%86%E0%AC%A1%E0%AC%BE%E0%AC%B2%E0%AC%BF%E0%AC%AE%E0%AD%81%E0%AC%AE%E0%AC%BE%E0%AC%ACAdalimumabAdalimumabe%D0%90%D0%B4%D0%B0%D0%BB%D0%B8%D0%BC%D1%83%D0%BC%D0%B0%D0%B1AdalimumabAdalimumabAdalimumabAdalimumab%D0%90%D0%B4%D0%B0%D0%BB%D1%96%D0%BC%D1%83%D0%BC%D0%B0%D0%B1AdalimumabQ348260%E9%98%BF%E9%81%94%E6%9C%A8%E5%96%AE%E6%8A%97
about
P1889
polyarthritisreactive arthritisCrohn's diseaseulcerative colitispyoderma gangrenosumarthritisrheumatoid arthritisspondylitisiritiscolitisuveitisgranuloma annulareankylosing spondylitisosteoarthritis susceptibility 1Guttate psoriasisarthropathypityriasis rubra pilarisirritable bowel syndromeBehcet's disease
P2176
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid ArthritisEffects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisA Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)Effects of Abatacept on Myocarditis in Rheumatoid ArthritisAdalimumab Microneedles in Healthy VolunteersStudy to Evaluate the Safety and Efficacy of Adalimumab in MPS I and IIStudy of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic ArthritisStudy of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisStudy of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug TherapyStudy of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisExtension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisMulticenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisUVB-311nm After Initial Slow Response to Adalimumab in PsoriasisPrimary UVB-311nm and Adalimumab in Psoriasis PatientsPositron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)Open-Label Adalimumab for Ulcerative Colitis PatientsStudy of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid ArthritisA Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid ArthritisA Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's DiseaseA Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's DiseaseEfficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical PracticeDocumentation of Humira in Psoriasis Patients in Routine Clinical PracticeGreek Study of the Quality of Life in Patients With Psoriasis Treated With AdalimumabDrug Use Investigation for Humira® - All Patient Investigation for Rheumatoid ArthritisSafety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid ArthritisStudy of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF BlockerRemission in Subjects With Crohn's Disease, Open Label ExtensionStudy of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis SuppurativaEfficacy and Safety Study of Adalimumab in Treatment of Hidradenitis SuppurativaADALISKIAS: Adalimumab for Acute Disc ProlapseHUmira in Psoriatic ArthritisA Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in ChinaPharmacokinetics and Safety Study of BI 695501 in Healthy SubjectsA Crossover Study of the Safety and Tolerability of Two Formulations of AdalimumabStudy to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to MethotrexateBiomarkers of Anti-TNF Treatment in IBD
P4844
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitisAdalimumab for treating rheumatoid arthritisAdalimumab for treating rheumatoid arthritisAdalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trialsEffect of adalimumab on neutrophil function in patients with rheumatoid arthritisKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialAdalimumab in the management of Behçet's diseasePsoriasis-like eruption induced by adalimumab in a patient with rheumatoid arthritis : a case report and review of literatureEffect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular ViewSpotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativaEfficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsProfile of adalimumab and its potential in the treatment of uveitisAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisTumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytesA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabAdalimumab for the treatment of rheumatoid arthritisHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialSoluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placeboCholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragmentsComparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related TolerabilityIndependent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory StudyAnti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort StudyAssessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to AdalimumabAdalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the LiteratureConsistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).Seborrhoeic dermatitis and a herpes zoster infection developed during treatment with adalimumab due to Crohn's diseaseSafety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
P921
Q1274464-E8BAB6CF-A9A0-49B9-9B2F-5FEBEEDF6E3CQ1327700-1528E0EB-D703-478F-9F59-A72AFB9AA588Q1472-A1D76718-F843-45B0-BBA8-5C1D59DC1674Q1477-5ED882C2-D72E-4199-B633-394EE58E599FQ1526459-6DB6C161-FECF-4CD0-ADB9-4B15AB14EF49Q170990-4F189C2A-799E-4767-B0D0-1DB603B8ADD0Q187255-F931E369-2664-4BFA-948F-5831341D1351Q2165411-D0A15A09-D6B9-44C7-970B-DCF37F6B51EEQ2346396-38CD52DF-E675-442C-9C44-3F61531E07CAQ2453464-9278D7D6-7093-40B1-95B6-14B7E3B18E37Q280027-53CA6F88-DBD8-433D-AEB5-B8F7C693B679Q455085-CB73754D-7AA8-4433-B249-9EC9990180F4Q52849-13E48CB3-092B-48D0-950E-F81DAB5CC47BQ55781316-CA34FF92-13AD-4BE1-971A-789BA50FF9CEQ5621891-293AFFA4-8858-4C0D-BCFB-08B57E503424Q708176-22B6911E-B430-4410-85BA-F8674534000DQ766856-E4B527E9-CFF8-4D7B-A56D-5F3E0672178CQ838966-94A749F3-E0D7-4BB7-9255-D02D8F4FCDEAQ911427-064E76D2-E38D-4F92-9049-3E570EE7478E
P2176
Q61727944-C5FDB47A-8465-4ACF-AF15-93889AC39FAFQ61894258-EE2DFD6A-8F65-4ADB-A104-E309D681CFC2Q61894404-7B036EBB-8F70-4D62-8D3E-D128764B1B08Q61902740-A331144A-42DB-4987-8F84-4138D4A59E92Q61907093-21DD2FEF-C2CF-4C03-9A4F-866CA71EB769Q61909831-F1280A9F-C7D5-43C8-947B-C4CE16B0D753Q61914347-1177A509-1D99-43B7-9E29-10E6FE027D77Q61914363-A86D22EE-386D-46A0-AD5C-AE0818935CA5Q61914364-41F1B1E5-F16B-4932-A3B1-0E72DB108BA1Q61914387-22E96087-0D82-4DC1-B165-FF79186E8C82Q61914388-CCD27702-8C3C-4769-A317-49AA923422EFQ61914395-22203832-3BB1-4799-B1E9-C6356C74F920Q61915122-8586E39D-1BDC-4989-9AA4-C6EB338AD2AAQ61915147-67526266-61E6-4D3C-B93A-AB7D33F857CEQ61917394-9376629C-E9E8-4F41-B546-8A61EFCECA20Q61921316-BE951C49-F172-4422-B1AB-47847F2E27AFQ61921357-D4966587-493C-4CDD-86FE-4EBADC4037E7Q61921850-5929885F-F093-449F-9217-9B7A0F72CDC8Q61921925-A027B68D-4177-4E85-8BC6-1C17FDE60A4AQ61923776-C2E5B946-645C-461F-B0DE-5FC0539B4786Q61924488-F7979E1C-1DA2-4119-AA08-0501CA490AE6Q61924617-CFE9372D-6CE5-4417-AE8D-3DDBD669389FQ61938046-B96B1F47-B275-498D-B970-39A2F9F000F7Q61938048-B9E8FC7A-C7EF-4B98-9D9F-299B177B46F9Q61938060-D9CA69DA-623F-4025-B4B5-DFAAE2C30FE3Q61938076-9877422C-1B31-4BBD-AB04-4D3AE9338034Q61938158-B643D47E-66A5-475C-80D0-6EBB791C3B04Q61938159-46AC8908-53D8-4C0F-824F-4FB9C709C47BQ61938609-11D07D07-224A-4983-96F4-4A415DFF2454Q61938827-C1096254-19EA-488C-89C9-48AA5F0AA80EQ61939431-A7A3DAFA-46E5-4EAB-83D1-5BD537EDFBC5Q61956023-299295C9-A6B4-4819-A299-8546DA4002A3Q61956031-8E6A6BA8-24C3-4553-A931-1890EEDBF2DBQ61956176-E1886454-35F0-4698-8352-973797FE8833Q61956566-6BE2B9C9-A27B-43DF-8A1B-9646DBA14BDAQ61956814-7126F866-624D-43CE-B51E-FDE8B9EDC0EEQ61957101-8CA254DF-6BF2-45CA-B6D0-154B52B8AC90Q61957501-F1EEFFA3-2737-4FFD-9EBE-24DC43637709Q61957736-4A2A07C5-CEB8-4EA0-A44B-305535AEC748Q61975241-FF2EA973-B29D-4DE4-AFD3-7C1F4EC16C41
P4844
description
Farmakolojik İlaç
@tr
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Adalimumab
@de
Adalimumab
@fi
Adalimumab
@it
Adalimumab
@nl
Adalimumab
@sh
Adalimumab
@sl
Adalimumab
@sr
Adalimumab
@tr
Adalimumab
@vi
Aδαλιμουμάμπη
@el
type
label
Adalimumab
@de
Adalimumab
@fi
Adalimumab
@it
Adalimumab
@nl
Adalimumab
@sh
Adalimumab
@sl
Adalimumab
@sr
Adalimumab
@tr
Adalimumab
@vi
Aδαλιμουμάμπη
@el
altLabel
331731-18-1
@fr
Adalimurabe
@pt
D2E7
@en
FKB327
@en
Humira
@de
Humira
@el
Humira
@en
Humira
@fr
Humira
@nl
Humira
@pt
prefLabel
Adalimumab
@de
Adalimumab
@fi
Adalimumab
@it
Adalimumab
@nl
Adalimumab
@sh
Adalimumab
@sl
Adalimumab
@sr
Adalimumab
@tr
Adalimumab
@vi
Aδαλιμουμάμπη
@el
P2175
P2868
P31
P486
P592
P6366
P646
P665
P2115
N0000148789
P2175
P2275
Adalimumab
@en
P231
331731-18-1
P232
P2566
100.224.376
P267
P3345
P3417
Adalimumab